Metalloproteinase inhibitor 1 (TIMP1) (TIMP1)

Metalloproteinase inhibitor 1 (TIMP1) is a multifunctional glycoprotein that serves as a primary endogenous regulator of matrix metalloproteinases (MMPs), a family of enzymes responsible for the degradation and remodeling of the extracellular matrix (ECM). By forming stable, non-covalent 1:1 complexes with active MMPs, TIMP1 maintains tissue homeostasis and governs physiological processes such as wound healing, development, and erythropoiesis. Beyond its canonical role as a protease inhibitor, TIMP1 functions as a cytokine and growth factor by binding to cell-surface receptors like CD63 and CD82, thereby activating signaling pathways such as MAPK and PI3K/Akt that promote cell survival and proliferation. In pathological contexts, dysregulated TIMP1 expression is a hallmark of various diseases; elevated levels are frequently associated with cancer progression, metastasis, and poor prognosis, as well as the development of organ fibrosis in the liver, lungs, and kidneys. Consequently, TIMP1 is a significant clinical biomarker, notably as part of the Enhanced Liver Fibrosis (ELF) score and as a prognostic indicator in oncology. Therapeutic strategies targeting TIMP1 focus on modulating its expression or activity to restore the MMP/TIMP balance, though challenges such as its short half-life and context-dependent biological roles must be addressed.

Other names

Tissue inhibitor of metalloproteinases 1TIMP-1Erythroid-potentiating activityEPAFibroblast collagenase inhibitorCollagenase inhibitorHuman collagenase inhibitorHCICLGIEPO

Drugs targeting TIMP1 primarily act by modulating its expression levels or providing exogenous recombinant protein to restore the balance between matrix metalloproteinases (MMPs) and their inhibitors. For instance, retinoids can induce TIMP1 expression to counteract excessive matrix degradation, while experimental approaches like siRNA or neutralizing antibodies aim to downregulate TIMP1 in cancer or fibrotic settings where its overexpression promotes disease progression.